Puma Biotechnology (PBYI) Tax Provisions (2020 - 2026)
Puma Biotechnology's (PBYI) quarterly Tax Provisions came in at $326000.0 in Q1 2026, up 11.26% YoY from $293000.0 in Q1 2025, and up 33.06% on a QoQ basis from $245000.0 in Q4 2025.
Puma Biotechnology (PBYI) Tax Provisions (2020 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 7 years of Tax Provisions data on file, last reported at $326000.0 in Q1 2026.
- Quarterly Tax Provisions rose 11.26% year-over-year to $326000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 416.13% YoY) and the FY2025 annual result came in at $1.2 million, up 612.57% from the prior year.
- Tax Provisions rose to $326000.0 in Q1 2026, from $245000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $399000.0 in Q3 2025 to a low of -$714000.0 in Q4 2024.
- A 5-year average of $156058.8 and a median of $220000.0 in 2024 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2023 — Tax Provisions soared 322.36% — and 2024, when it sank 299.44%.
- Tracing PBYI's Tax Provisions over 5 years: stood at -$161000.0 in 2022, then soared by 322.36% to $358000.0 in 2023, then slumped by 299.44% to -$714000.0 in 2024, then jumped by 134.31% to $245000.0 in 2025, then jumped by 33.06% to $326000.0 in 2026.
- The last three Tax Provisions figures came in at $326000.0 (Q1 2026), $245000.0 (Q4 2025), and $399000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 56,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56,000.00 |
| Mar 31, 2026 | 326,000.00 |
| Dec 31, 2025 | 245,000.00 |
| Sep 30, 2025 | 399,000.00 |
| Jun 30, 2025 | 310,000.00 |
| Mar 31, 2025 | 293,000.00 |
| Dec 31, 2024 | -714,000.00 |
| Sep 30, 2024 | 291,000.00 |
| Jun 30, 2024 | 378,000.00 |
| Mar 31, 2024 | 220,000.00 |
| Dec 31, 2023 | 358,000.00 |
| Sep 30, 2023 | 213,000.00 |
| Jun 30, 2023 | 187,000.00 |
| Mar 31, 2023 | 147,000.00 |
| Dec 31, 2022 | -161,000.00 |
| Sep 30, 2022 | 67,000.00 |
| Jun 30, 2022 | 57,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Dec 31, 2021 | 212,000.00 |
| Sep 30, 2021 | 37,000.00 |